Available in the shop
- Survodutide 10 mg — $539.70
Sold for in vitro laboratory research only — not for human or animal consumption. ≥99% purity specification.
Identification
| Field of research | Weight research |
|---|---|
| Formula | C192H289N47O61 |
| Molecular weight | 4232 g/mol |
| Also known as | GTPL13383, EX-A7878, BI456906, BI 456906 |
| PubChem | CID 168429725 |
Summary
Survodutide is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist.
From Wikipedia, available under CC BY-SA 4.0. Short description from Wikidata (CC0).
Published research
Titles are shown as published. Listing a paper is not an endorsement of its findings, and many papers on research peptides are laboratory or animal studies: the type of study is shown when PubMed records it.
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMANetwork Meta-AnalysisSystematic ReviewSinha B, Ghosal S · Obesity (Silver Spring), 2025 · PMID 40685589 · DOI
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityReviewResearch Support, Non-U.S. Gov'tDrucker DJ · Diabetes Care, 2024 · PMID 38843460 · DOI
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitisReviewSingh A, Sohal A, Batta A · World J Gastroenterol, 2024 · PMID 39735270 · DOI
- A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisClinical Trial, Phase IIRandomized Controlled TrialMulticenter StudySanyal AJ, Bedossa P, Fraessdorf M et al. · N Engl J Med, 2024 · PMID 38847460 · DOI
- Emerging pharmacotherapies for obesity: A systematic reviewSystematic ReviewKokkorakis M, Chakhtoura M, Rhayem C et al. · Pharmacol Rev, 2025 · PMID 39952695 · DOI
- Therapeutic horizons in metabolic dysfunction-associated steatohepatitisReviewResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tNewsome PN, Loomba R · J Clin Invest, 2025 · PMID 40590228 · DOI
- Weight management treatment in obesityReviewRubio-Herrera MA, Mera-Carreiro S · Med Clin (Barc), 2025 · PMID 40865172 · DOI
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trialClinical Trial, Phase IIMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tle Roux CW, Steen O, Lucas KJ et al. · Lancet Diabetes Endocrinol, 2024 · PMID 38330987 · DOI
Top 8 of 85 results, by relevance. See all on PubMed.
Search query "Survodutide"[Title/Abstract]
Data provenance
| Data | Source | Record |
|---|---|---|
| Chemical identity and structure | PubChem | CID 168429725 |
| Published literature | PubMed | Search on PubMed |
| Summary sentence | Wikipedia | Survodutide |
Data retrieved 2026-10-08. See About for the sources. How the data is collected and checked: Methods.